Baidu
map

Diabetes:二甲双胍和SGLT2抑制剂组合有效降低血糖水平

2014-08-06 佚名 生物谷

根据Diabetes杂志上的一项新研究证实:二甲双胍和SGLT2抑制剂组合后,可更有效地降低血糖水平,两药组合的降血糖功效显着高于单独用药。 在糖尿病的治疗中,不同口服的抗糖尿病药中的各种活性物质经常会组合在一起,以达到更有效降低血糖的目的。一种新的,非常有前途的方法:二甲双胍结合SGLT2抑制剂在2012年被批准。 Martin Hrabě de Angelis博士和Ludwig-M

根据Diabetes杂志上的一项新研究证实:二甲双胍和SGLT2抑制剂组合后,可更有效地降低血糖水平,两药组合的降血糖功效显着高于单独用药。

糖尿病的治疗中,不同口服的抗糖尿病药中的各种活性物质经常会组合在一起,以达到更有效降低血糖的目的。一种新的,非常有前途的方法:二甲双胍结合SGLT2抑制剂在2012年被批准。

Martin Hrabě de Angelis博士和Ludwig-Maximilians-Universität München、药品生产商赛诺菲-安万特公司合作,发现了这两种物质(二甲双胍和SGLT2抑制剂)是如何互为增强降血糖功效的。

SGLT2抑制剂能够增加尿中葡萄糖的排泄,从而降低血液中的糖。二甲双胍和SGLT2抑制剂组合能有效的、长期的降低血糖水平。

两药组合能有效降低血糖,尤其是饭后血糖峰值。在糖尿病小鼠中,二甲双胍和SGLT2抑制剂组合治疗,仅在两个星期内,就能导致长期血糖水平的改善。

二甲双胍和SGLT2抑制剂组合有效降低血糖的同时,产生的副作用也小。

原始出处:

Neschen S1, Scheerer M2, Seelig A2, Huypens P3, Schultheiss J4, Wu M2, Wurst W5, Rathkolb B4, Suhre K6, Wolf E7, Beckers J8, Hrabé de Angelis M9.Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 (SGLT2) inhibitor by suppressing endogenous glucose production in diabetic mice.Diabetes. 2014 Jul 28. pii: DB_140393. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
    2015-08-16 shuaijing1986

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
    2014-08-17 tulenzi
  3. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
    2015-04-11 x35042875

    糖尿病肾病进展风险的关系没有发现。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
    2014-10-17 智智灵药
  10. [GetPortalCommentsPageByObjectIdResponse(id=35696, encodeId=1f4c3569670, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Sun Aug 16 21:18:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793769, encodeId=81121e9376987, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Aug 17 01:39:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20657, encodeId=65d02065e3d, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972021, encodeId=911f19e2021df, content=<a href='/topic/show?id=c0fc89839ff' target=_blank style='color:#2F92EE;'>#血糖水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89839, encryptionId=c0fc89839ff, topicName=血糖水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Sep 21 22:39:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995467, encodeId=e03f199546e55, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 18 17:39:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636925, encodeId=f1d2163692506, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jul 20 08:39:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818687, encodeId=0e12181868e4a, content=<a href='/topic/show?id=4119981338a' target=_blank style='color:#2F92EE;'>#降低血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98133, encryptionId=4119981338a, topicName=降低血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Fri May 01 18:39:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901237, encodeId=2bc9190123ebc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 12 11:39:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759482, encodeId=f39a1e5948280, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Oct 17 04:39:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851191, encodeId=4609185119146, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 26 12:39:00 CST 2014, time=2014-12-26, status=1, ipAttribution=)]
    2014-12-26 jklm09

相关资讯

Lancet:每周一次dulaglutide PK 每天一次利拉鲁肽:疗效和安全性相当

7月10日在《柳叶刀》上在线发表的一篇研究证实,每周一次dulaglutide控制2型糖尿病患者HbA1c和血糖的疗效和安全性与每天一次利拉鲁肽相当。(Lancet  2014 Jul 10;) 在研究纳入的599例服用二甲双胍(至少1500mg/天)但血糖控制不充分的2型糖尿病患者中,两种胰高血糖素样肽-1(GPL-1)受体激动剂降低HbA1c的幅度和耐受性相似。 AWARD-

Diabetes Care:改善血糖控制,Dulaglutide优于二甲双胍

一项多国联合研究(AWARD-3研究)显示,每周一次胰高血糖素-1受体激动剂Dulaglutide在2型糖尿病患者血糖控制方面优于二甲双胍,两者安全性相似。论文5月19日在线发表于《糖尿病护理》(Diabetes Care)杂志。 这项52周双盲研究将患者分为dulaglutide 1.5 mg组、dulaglutide 0.75 mg组和二甲双胍组,旨在比较dulaglutide与二甲双胍治疗

曾庆平:二甲双胍,为何能成为长寿灵丹?

二甲双胍(metformin)是著名的降糖药,主要用来治疗2型糖尿病,但它对非酒精性脂肪肝病及癌症等多种人类疾病也有潜在治疗效果。更神奇的是,二甲双胍像热量限制一样能够延长生物的寿命,这已在线虫、大鼠和小鼠中得到证实。如此说来,二甲双胍堪称“神药”、“仙丹”! 6月2日,Science Daily网站报道了《美国科学院院报》(PNAS)刚刚在线发表的一篇最新论文,揭示二甲双胍通过“线粒体低毒

ADA 2014:DPPOS15年随访结果揭晓

糖尿病预防项目转归研究[TheDiabetesPrevention ProgramOutcomes Study(DPPOS)]源于1996年的糖尿病预防项目(DPP),评估强化生活方式干预和口服降糖药能否预防或延缓糖尿病高危人群疾病进展。6月16日的专场揭晓了DPPOS15年随访结果。 DPP纳入美国27个中心3234例糖尿病前期患者,随机接受安慰剂、二甲双胍(MET,850mg bid)和

Diabetes Obes Metab:早期联合治疗可获得更佳的降糖疗效

2型糖尿病防治指南推荐在二甲双胍单药治疗不能充分控制血糖时,可以考虑加用其他降血糖药物。然而,早期联合治疗是否可以为2型糖尿病患者带来健康结局获益仍不清楚。 为此,来自美国健康科学西部大学药学院的Olivia J. Phung教授及其团队进行了一项系统性回顾和荟萃分析,探讨早期联合治疗是否能为2型糖尿病患者带来健康结局获益。该研究结果发表在2014年05月的Diabetes, Obesity a

Lancet Diab & Endo:个性化二甲双胍治疗糖尿病的可能性

二甲双胍 (metformin) 是在 2 型糖尿病治疗中使用的一线口服剂,但是对于这种药物的血糖反应差异很大。了解遗传对二甲双胍反应的贡献或许会增加个性化二甲双胍治疗的可能性。 我们的目的是使用全基因组复杂性状分析 (GCTA) 方法,来确定对二甲双胍的血糖反应的遗传性。 在这项 GCTA 研究中,研究者们获得了参与苏格兰泰赛德糖尿病遗传学核查与调查 (GoDARTS) 研究的患者在接受二甲双

Baidu
map
Baidu
map
Baidu
map